The Cervical Cancer Prevention (CECAP) Program of the JHPIEGO Corporation, which is funded by the Bill and Melinda Gates Foundation through the Alliance for Cervical Cancer Prevention, is currently working on evaluating the safety, acceptability, feasibility, and programmatic effectiveness (SAFE) of a test and treat or refer approach to cervical cancer. This approach involves the use of visual inspection with acetic acid (VIA) to test for cancer or precancerous lesions and cryotherapy treatment of some precancerous lesions. CECAP conducts its work within the scope of the Alliance for Cervical Cancer Prevention. a group of five international organizations involved in cervical cancer prevention worldwide (AVSC, IARC, PAHO, PATH).

Once the first phase of CECAP's work involving SAFE demonstration projects is completed, CECAP will have evidence that non-physicians can safely provide VIA testing and immediate treatment with cryotherapy, they can identify which lesions need to be referred for management higher up in the health care delivery system, and that the approach is acceptable to the providers, women, and their families. Until this phase has been completed, however, CECAP is limited in the extent to which the training materials currently being evaluated can be distributed. That is, any materials related to training in either VIA or cryotherapy may only be distributed in the context of an organized VIA/cryotherapy training course. However, CECAP will maintain a list of requests for such materials so that they can be distributed to requesting individuals in the future.

The CECAP Program can distribute documents describing the rationale for cervical cancer prevention programs and the potential links of such programs to other reproductive health services as well as the suggested modes of managing precancerous disease. Educational materials describing risk factors associated with the disease (including the role of human papillomavirus) are also available for general distribution.